Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

EQRx Retracts Promise to Bring Low-Cost China Drugs to US

publication date: Nov 11, 2022

Boston’s EQRx backed off its promise to bring innovative medicines to the US market at a 50%-70% discount from big pharma prices. Now, the company plans to seek “market prices” for two drugs in-licensed from China companies and will drop development of an indication for a third drug. The abrupt change follows the FDA’s policy requiring companies to conduct US Phase III trials of new drugs rather than basing NDAs completely on China data. More Phase III trials means higher development costs, destroying EQRx’s business plan. More details....

Stock Symbol: (NSDQ: EQRX)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital